Genmab A/S (GMAB) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Which has more volatility & risk, TAK or GMAB?

Takeda Pharmaceutical has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Does the media prefer TAK or GMAB?

In the previous week, Genmab A/S had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Genmab A/S and 4 mentions for Takeda Pharmaceutical. Genmab A/S's average media sentiment score of 0.81 beat Takeda Pharmaceutical's score of 0.24 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of TAK or GMAB?

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Is TAK or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to Takeda Pharmaceutical's net margin of 3.20%. Genmab A/S's return on equity of 21.03% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.20%	10.50%	5.10%
Genmab A/S	37.53%	21.03%	16.98%

Do analysts recommend TAK or GMAB?

Genmab A/S has a consensus target price of $40.80, suggesting a potential upside of 24.62%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Which has higher earnings & valuation, TAK or GMAB?

Genmab A/S has lower revenue, but higher earnings than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$30.09B	1.51	$712.33M	$0.30	47.73
Genmab A/S	$3.12B	6.73	$1.14B	$1.99	16.45

Summary

Genmab A/S beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.